José Luis Fuster Soler

Ferrandez-Pujante A, Perez-Silva A, Serna-Munoz C, Fuster-Soler JL, Galera-Minarro AM, Cabello I, Ortiz-Ruiz AJ. Prevention and Treatment of Oral Complications in Hematologic Childhood Cancer Patients: An Update. Children (Basel). 2022 Apr 15;9(4):566. doi: 10.3390/children9040566. PubMed PMID: 35455610; PubMed Central PMCID: PMC9029683.

AÑO: 2022; IF: 2.835

35455610

Martínez-Sánchez MV, Fuster JL, Campillo JA, Galera AM, Bermúdez-Cortés M, Llinares ME, Ramos-Elbal E, Pascual-Gázquez JF, Fita AM, Martínez-Banaclocha H, Galián JA, Gimeno L, Muro M, Minguela A. Expression of NK Cell Receptor Ligands on Leukemic Cells Is Associated with the Outcome of Childhood Acute Leukemia. Cancers (Basel). 2021 May 11;13(10). pii: 2294. doi: 10.3390/cancers13102294. PubMed PMID: 34064810; PubMed Central PMCID: PMC8151902.

AÑO: 2021; IF: 6.575

34064810

Gimeno L, González-Lozano I, Soto-Ramírez MF, Martínez-Sánchez MV, López-Cubillana P, Fuster JL, Martínez-García J, Martínez-Escribano J, Campillo JA, Pons-Fuster E, Ferri B, López-Abad A, Muro M, Minguela A. CD8+ T lymphocytes are sensitive to NKG2A/HLA-E licensing interaction: role in the survival of cancer patients. Oncoimmunology. 2021 Oct 14;10(1):1986943. doi: 10.1080/2162402X.2021.1986943. eCollection 2021. PubMed PMID: 34676148; PubMed Central PMCID: PMC8525952.

AÑO: 2021; IF: 7.723

34676148

Muñoz Builes M, Vela Cuenca M, Fuster Soler JL, Astigarraga I, Pascual Martínez A, Vagace Valero JM, Tong HY, Valentín Quiroga J, Fernández Casanova L, Escudero López A, Sisinni L, Blanquer M, Mirones Aguilar I, González Martínez B, Borobia AM, Pérez-Martínez A. Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia. BMJ Open. 2020 Jan 8;10(1):e029642. doi: 10.1136/bmjopen-2019-029642. PubMed PMID: 31919123; PubMed Central PMCID: PMC6955478.

AÑO: 2020; IF: 2.692

31919123

Vega-García N, Perez-Jaume S, Esperanza-Cebollada E, Vicente-Garcés C, Torrebadell M, Jiménez-Velasco A, Ortega M, Llop M, Abad L, Vagace JM, Minguela A, Pratcorona M, Sánchez-Garcia J, García-Calderón CB, Gómez-Casares MT, Martín-Clavero E, Escudero A, Riñón Martinez-Gallo M, Muñoz L, Velasco MR, García-Morin M, Català A, Pascual A, Velasco P, Fernández JM, Lassaletta A, Fuster JL, Badell I, Molinos-Quintana Á, Molinés A, Guerra-García P, Pérez-Martínez A, García-Abós M, Robles Ortiz R, Pisa S, Adán R, Díaz de Heredia C, Dapena JL, Rives S, Ramírez-Orellana M, Camós M. Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment. Front Pediatr. 2021 Feb 5;8:614521. doi: 10.3389/fped.2020.614521. eCollection 2020. PubMed PMID: 33614543; PubMed Central PMCID: PMC7892614.

AÑO: 2020; IF: 3.418

33614543